An observational study in Sarcoma, Bone, Sarcoma, Soft Tissue and Gait Disorder, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged 5 Years to 20 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by St. Jude Children's Research Hospital · Observational
Among 19 studies in Osteosarcoma by St. Jude Children's Research Hospital — 7 open to participants now, 8 under way, none of them phase 3. Osteosarcoma · St. Jude Children's Research Hospital.
Among the 19 studies in Osteosarcoma by St. Jude Children's Research Hospital, this one is one of 3 that started in 2026, is one of 4 observational ones, and was the 18th registered.
488 studies on the registry are indexed under Osteosarcoma; 124 are open to participants now.
This study's planned enrollment of 300 is above the median of 100 across 99 observational studies indexed under Osteosarcoma.
Browse Osteosarcoma studies →7 of the 19 studies in Osteosarcoma by St. Jude Children's Research Hospital are open now, in 2 countries. Each count lists the studies.
Of the 101 Osteosarcoma studies recruiting now, 42 (42%) set no upper age limit and 55 (54%) stop at 75 or younger; 76 take children under 18; 3 take healthy volunteers.
This study: 5 Years to 20 Years · all sexes · healthy volunteers too.
The full table on the hub →19 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 3 started in 2026.
Median enrollment 50 across the 15 interventional studies, 188 across the 4 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
St. Jude Children's Research Hospital is the lead sponsor of 440 studies on the registry; 102 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.
3 of the studies in Osteosarcoma by St. Jude Children's Research Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04901702St. Jude Children's Research HospitalStudy of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | 2026-12-31 |
| NCT04897321St. Jude Children's Research HospitalB7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | 2027-03-01 |
| NCT00840047St. Jude Children's Research HospitalMethionine PET/CT Studies In Patients With Cancer | 2027-07-27 |
Among the 19 studies in Osteosarcoma by St. Jude Children's Research Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
The goal of DEEPGAIT study is to determine how serious walking problems are for pediatric cancer patients who have had orthopedic surgery, how they change over time, and what can be done to help. Healthy participants without cancer will also be included in this study in order to better understand the difference in walking problems between the 2 groups.
DEEPGAIT is a long term study that uses advanced tools-including 3D motion capture, muscle sensors, force plates, and wearable devices-to take a detailed look at how these patients move. Their results are compared to healthy children of the same age and sex.
PRIMARY OBJECTIVES
SECONDARY OBJECTIVES
The DEEPGAIT study aims to understand how walking ability changes before and after lower limb surgery by using 3D motion capture technology, wearable sensors, movement testing, and surveys. The study will also compare patients' walking patterns to healthy children and teens to create a reference library of normal gait across age groups.
Children ages 5-20 years who need surgery for bone sarcoma, soft tissue sarcoma, or steroid induced AVN will take part in several assessments over five years. Healthy peers ages 5-20 years will participate once. All participants will complete lab based walking tests, functional assessments, questionnaires, and a 7 day at home wearable sensor study.
The main goal is to measure walking speed one year after surgery and identify factors that influence long term mobility, recovery, and quality of life. The results may help doctors improve rehabilitation and better support young people recovering from cancer related orthopedic conditions.
This study includes children, teens, and young adults ages 5-20 who receive care at St. Jude and need lower limb orthopedic surgery for bone sarcoma, soft tissue sarcoma, or steroid induced avascular necrosis. These participants will complete walking and movement assessments before surgery and again at several timepoints afterward. The study will include healthy volunteers ages 5-20, mainly friends or siblings of patients, who do not have conditions that affect walking. Healthy participants complete a single visit to provide comparison data. In total, the study will include 150 pediatric cancer patients and 150 healthy controls to help researchers better understand walking patterns and recovery after surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cases:
Controls:
Exclusion Criteria
Cases:
Controls:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group includes children and teens (ages 5-20 years) who need surgery on a leg joint or bone because of a cancer related condition. They take part in the study several times: before surgery, and then 1, 2, and 5 years after surgery. They also do a week of at home monitoring after the 1 year visit.
Diagnostic Test: Lab based 3D Gait Assessment · Device: Wearable Inertial Sensors (In Lab and Remote) · Other: Functional Testing & Patient Reported Outcomes · Other: Remote Wearable Sensor Assessment
This group includes healthy children and teens (ages 5-20 years) who are matched by age and sex to participants in the surgery group. They take part in the study once, around the same time the surgery participant reaches their 1 year visit.
Diagnostic Test: Lab based 3D Gait Assessment · Device: Wearable Inertial Sensors (In Lab and Remote) · Other: Functional Testing & Patient Reported Outcomes · Other: Remote Wearable Sensor Assessment
Marker based motion capture, surface EMG, instrumented force plates, spatiotemporal analysis, and 10 meter walking trials conducted barefoot and with shoes (or prosthesis/assistive devices if applicable). Captures walking speed (primary outcome), joint kinematics, kinetics, EMG activity, and detailed gait parameters.
Sensors placed bilaterally on the midfoot and lower leg, plus a wrist sensor. Capture gait velocity, spatiotemporal metrics, and 3D ankle kinematics during lab assessments and during a 7 day post T1 monitoring period in real world settings. Data processed using accelerometer, gyroscope, and magnetometer fusion.
Comprehensive functional evaluation including: * Anthropometrics and alignment * Strength testing (hand held dynamometry) * Joint range of motion * Balance (BOT 3) * Endurance (6 minute walk test) * Peripheral sensorimotor integrity (Ped mTNS) * Patient reported outcomes: KOOS, HOOS, PEG, Oxford Ankle Foot Questionnaire for Children, PROMIS Physical Activity/Function/Parent Proxy
Seven day at home/in community gait monitoring after the T1 visit. Participants wear midfoot, lower leg, and wrist sensors daily, complete a 5 minute structured indoor walking task each day, and record adherence, tolerability, fatigue, and satisfaction in an online study diary. Training video and tablet provided.
Gait velocity (meters/second)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1
Walking cadence (steps/minute)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Step length with variability and asymmetry, stride length (meters)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1
Six-Minute Walk Test (meters)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Step width and variability (meters)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Swing and stance time with asymmetry, step time with variability and asymmetry (seconds)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Step velocity variability (meters/second)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Gait Profile Score
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Gait Deviation Index
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Pelvic tilt, obliquity, and rotation angles (◦)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Hip and knee flexion/extension, abduction/adduction, and rotational angles (⸰)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Ankle dorsiflexion/plantarflexion, inversion/eversion,and abduction/adduction angles (⸰)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Popliteal angle (⸰)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Hip peak force, flexor, abductor, and extensor strength (Newtons)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Knee peak force, flexor and extensor strength (Newtons)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Ankle peak force, plantarflexor and dorsiflexor strength (Newtons)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Quadricep lag
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Hip, knee, and ankle torque (Nm/kg)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Hip, knee, and ankle power (W/kg)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Hip and knee flexor & extensor EMG amplitude, ankle dorsiflexor & plantarflexor EMG amplitude (µV)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Pediatric Modified-Total Neuropathy Scale (ped-mTNS) (0-24 points)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Bruininks Oseretsky Test of Motor Proficiency 3rd edition (BOT-3) balance subtest (standardized score)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Knee Injury and Osteoarthritis Outcome Score (KOOS), Hip Disability and Osteoarthritis Outcome Score (HOOS), Oxford Ankle Foot Questionnaire for Children (0-100)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
PEG (ultra-brief pain measure derived from the Brief Pain Inventory) (1-10)
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
PROMIS Physical Activity, Physical Function and Parent Proxy Questionnaires
Descriptive statistics will be reported for case participants, both longitudinally and in comparison with controls, at baseline, 1, 2, and 5 years post-surgery. Descriptive statistics will be reported for controls at Day 1.
Time frame: Case participants: Baseline/study entry, 1, 2, and 5 years post-surgery. Control participants: Day 1.
Plan to share: Yes — Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be made available at the time of article publication.
Access criteria: Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.
Started Jun 2026 (actual). Primary completion is estimated for Jan 2031, 55 months after the start.
Of 41 observational studies under Osteosarcoma, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 228. This study's planned 55 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
St. Jude Children's Research Hospital →